SHIOKAWA et al. V. MAIENFISCH et al. - Page 47



                     issued a restriction requirement.  (SX 2005, Office Action mailed June 27, 1996, p. 5).  The restriction                                                          

                     requirement identified five distinct groups of inventions.  The restriction did not identify 1,3,5-                                                               

                     oxadiazines as one of the independent and distinct inventions, rather the 1,3,5-oxadiazines fell into the                                                         

                     fifth group which encompassed “any other species instance in claim 1 not grouped above.”  (SX 2005,                                                               

                     p. 2).   In response to the restriction requirement, Shiokawa decided to provisionally elect, with                                                                

                     traverse, the 1,3,5-oxadiazines compounds, a subgenus not specifically identified by the examiner                                                                 

                     in the restriction requirement.  (SX 2005, pages 2 and 5).                                                                                                        



                                                     vii.       Lack of Written Description Finding is Consistent with Statement Made                                                  
                                                                by Several of the ‘146 Inventors                                                                                       

                                Our analysis is consistent with that of several of the inventors named in the ‘146 patent.                                                             

                     Specifically, Japanese Application No. 6-35254 (laid open no. 7-224062) was filed on February 9,                                                                  

                     1994 (‘254 application”).  Koichi Moriya and Yumi Hattori are listed as inventors on both the ‘254                                                                

                     application and the ‘146 patent.  (Compare SX 2003, front page and MX 1005, p. 1).  The JP ‘254                                                                   

                     application specifically describes both 1,3,5-oxadiazines and 1,3,5-thiadiazines, i.e., X is oxygen or                                                            

                     sulfur in Formula (I). (MX 1005, p. 4).   Indeed, claim 2 of the ‘254 application is directed to 1,3,5-                                                           
                     oxadiazines that are fully encompassed by the subgenus of claim 1 of the ‘146 patent.    Yet, the JP                       15                                     

                     ‘254 application states:                                                                                                                                          

                                PRIOR ART AND TECHNICAL ISSUES  Laid-open Patent Application Hei 2-                                                                                    
                                235881 [i.e., JP application ‘943, the foreign priority document relied upon by the ‘146                                                               
                                patent], which was known prior to the submission of this application, describes nitro or                                                               


                                15Note that claim 2 of the JP ‘254 application defines A as including 6-chloro-3-pyridyl                                                               
                     whereas claim 1 of the ‘146 patent defines A as including 2-chloropyridin-5-yl.  While named                                                                      
                     differently, these are the same substituents.                                                                                                                     
                                                                                         45                                                                                            





Page:  Previous  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  Next 

Last modified: November 3, 2007